Oxacillin

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
화요일, 3월 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Methicillin-resistant Staphylococcus aureus, NYSE, Infection, VRE, Daptomycin, Phenotype, Enterococcus-1 RNA motif, Methicillin, MRSA, Vancomycin, Oxacillin, Vaccine, Antibiotics, Oragene

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

Retrieved on: 
화요일, 6월 14, 2022
Bloodstream infections, Subclinical infection, Campaign, Breakthrough therapy, Death, Pseudomonas aeruginosa, Șaeș, Vancomycin, Pneumonia, Conference, HHS, Forward-looking statement, CEO, Lysin, Security (finance), Staphylococcus, Hypersensitivity, U.S. Securities and Exchange Commission, Oxacillin, Nasdaq, Maintenance, Endocarditis, Enterobacter, Rockefeller University, DLA, FDA, GLOBE, MSSA, Patient, Mortality, BSI PAS 2060, Biofilm, BARDA, Daptomycin, Trial of the century, Methicillin-resistant Staphylococcus aureus, Acinetobacter baumannii, Clinical trial, ASPR, CFU, Infection, SOC, MRSA, CFU-GEMM, MIC, Osteomyelitis, Bacteria, S. aureus, Peptide, Antibiotics, Pharmaceutical industry

These data were recently presented at the ASM Microbe Conference held in Washington, D.C. from June 9-13, 2022.

Key Points: 
  • These data were recently presented at the ASM Microbe Conference held in Washington, D.C. from June 9-13, 2022.
  • These results demonstrate that lysins offer a potentially effective strategy for treating implant-associated MRSA osteomyelitis infections.
  • These in vitro studies demonstrate the low propensity for the development of resistance to exebacase in both MRSA and methicillin-sensitive S. aureus (MSSA) strains.
  • 28-day serial passage resistance assays demonstrated that the minimum inhibitory concentration (MIC) of exebacase was not increased against MRSA and MSSA.

TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2 in Scientific Reports

Retrieved on: 
월요일, 9월 13, 2021
Hyperuricemia, Nature, Probenecid, Cloxacillin, FDA, Methicillin, Orthomyxoviridae, CEO, University, Plasma, Doctor of Philosophy, Manuscript, Patient, Doctor of Pharmacy, Infection, Severe acute respiratory syndrome coronavirus 2, Pharmacokinetics, COVID-19, Ampicillin, Gout, Degenerative disease, Scientific Reports, Oxacillin, Pharmaceutical industry, Vaccine

These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.

Key Points: 
  • These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.
  • "These data demonstrate a very potent antiviral effect of TD-213 against SARS-CoV-2," said Ralph Tripp, PhD.
  • Probenecid is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile.
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.